Stemrim
A biotech company aiming to develop regeneration-inducing medicines.
Launch date
Market cap
AUD311m
Enterprise valuation
AUD207m (Public information from Sep 2024)
Share price
JPY447 4599.T
Osaka Osaka Prefecture (HQ)
Financials
Estimates*
| JPY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.1b | 1.4b | 23.0m | 2.4b | 1.0b | 1.0b | 540m |
| % growth | - | (33 %) | (98 %) | 10128 % | (57 %) | - | (46 %) |
| EBITDA | 369m | (540m) | (1.9b) | 193m | (2.1b) | (1.1b) | (2.1b) |
| % EBITDA margin | 18 % | (39 %) | (8368 %) | 8 % | (210 %) | (108 %) | (392 %) |
| Profit | 348m | (582m) | (1.9b) | 168m | (2.1b) | (1.1b) | (2.1b) |
| % profit margin | 17 % | (42 %) | (8480 %) | 7 % | (210 %) | (108 %) | (393 %) |
| EV / revenue | 17.0x | 20.6x | 1784.3x | 19.6x | 27.5x | 27.5x | 50.9x |
| EV / EBITDA | 96.5x | -53.4x | -21.3x | 239.3x | -13.1x | -25.5x | -13.0x |
| R&D budget | 1.4b | 1.5b | 1.4b | 1.6b | - | - | - |
| R&D % of revenue | 65 % | 109 % | 6186 % | 67 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
$6.7m | Late VC | ||
| N/A | JPY1.0b | Early VC | |
JPY200m | Early VC | ||
JPY745m | Late VC | ||
* | N/A | N/A | IPO |
| Total Funding | AUD33.5m | ||
Related Content
Recent News about Stemrim
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.